Studies on the molecular properties of alpha-synuclein and the mechanisms of alpha-synuclein-related pathology bear important implications for our understanding of the neurodegenerative process that underlies PD. In particular, molecular interactions and toxic mechanisms that promote the tendency of alpha-synuclein to aggregate could also play a role in the development of the typical intraneuronal inclusions (i. e., Lewy bodies) seen in PD brain. Furthermore, elucidating the relationship between alpha-synuclein aggregation and neuronal injury could help to explain the role of Lewy bodies in nigrostriatal degeneration in PD. This integrative Research Project is intended to bridge two parent grants, both of which investigate the pathophysiology of alpha-synuclein. Results of studies in progress indicate that interactions between alpha-synuclein and neurotoxicants can induce protein aggregation and possibly contribute to neurodegeneration. The new proposed experiments are designed to provide a mechanistic basis for these pathological events. They will assess the role of oxidative stress as a key factor for the development of alpha-synuclein-containing inclusions and alpha-synuclein-induced neuronal injury, and determine whether the presence of dopamine within nigrostriatal neurons renders these cells particularly vulnerable to oxidative stress-mediated alpha-synuclein pathology.

Agency
National Institute of Health (NIH)
Institute
National Institute of Environmental Health Sciences (NIEHS)
Type
Specialized Center--Cooperative Agreements (U54)
Project #
1U54ES012077-01
Application #
6661796
Study Section
Special Emphasis Panel (ZES1)
Project Start
2002-08-26
Project End
2007-07-31
Budget Start
Budget End
Support Year
1
Fiscal Year
2002
Total Cost
Indirect Cost
Name
Parkinson's Institute
Department
Type
DUNS #
614259935
City
Sunnyvale
State
CA
Country
United States
Zip Code
94085
Koga, Shunsuke; Aoki, Naoya; Uitti, Ryan J et al. (2015) When DLB, PD, and PSP masquerade as MSA: an autopsy study of 134 patients. Neurology 85:404-12
Goldman, Samuel M; Kamel, Freya; Ross, G Webster et al. (2014) Peptidoglycan recognition protein genes and risk of Parkinson's disease. Mov Disord 29:1171-80
McGuire, V; Van Den Eeden, S K; Tanner, C M et al. (2011) Association of DRD2 and DRD3 polymorphisms with Parkinson's disease in a multiethnic consortium. J Neurol Sci 307:22-9
Popat, R A; Van Den Eeden, S K; Tanner, C M et al. (2011) Coffee, ADORA2A, and CYP1A2: the caffeine connection in Parkinson's disease. Eur J Neurol 18:756-65
Quik, Maryka; Campos, Carla; Parameswaran, Neeraja et al. (2010) Chronic nicotine treatment increases nAChRs and microglial expression in monkey substantia nigra after nigrostriatal damage. J Mol Neurosci 40:105-13
Peng, Jun; Oo, May Lin; Andersen, Julie K (2010) Synergistic effects of environmental risk factors and gene mutations in Parkinson's disease accelerate age-related neurodegeneration. J Neurochem 115:1363-73
Mak, Sally K; McCormack, Alison L; Manning-Bog, Amy B et al. (2010) Lysosomal degradation of alpha-synuclein in vivo. J Biol Chem 285:13621-9
Kaur, Deepinder; Rajagopalan, Subramanian; Andersen, Julie K (2009) Chronic expression of H-ferritin in dopaminergic midbrain neurons results in an age-related expansion of the labile iron pool and subsequent neurodegeneration: implications for Parkinson's disease. Brain Res 1297:17-22
Chinta, Shankar J; Rane, Anand; Yadava, Nagendra et al. (2009) Reactive oxygen species regulation by AIF- and complex I-depleted brain mitochondria. Free Radic Biol Med 46:939-47
Peng, Jun; Stevenson, Fang Feng; Oo, May Lin et al. (2009) Iron-enhanced paraquat-mediated dopaminergic cell death due to increased oxidative stress as a consequence of microglial activation. Free Radic Biol Med 46:312-20

Showing the most recent 10 out of 39 publications